诺和诺德总裁兼CEO周赋德：中国的“双循环”战略令我印象深刻

原标题：“我的2020” | 诺和诺德总裁兼CEO周赋德：中国的“双循环”战略令我印象深刻

来源：中国发展高层论坛

“CDF之声”栏目旨在汇聚关注、支持和参与论坛的重要商业领袖，向国内公众和国际社会传递论坛与会代表的心声。

2020年是个不平凡的年份。2020年，新冠疫情席卷全球，全球经济政治不确定性增强，各行业面临全新的机遇与挑战。

历经2020年的洗礼，站在全新的2021年，世界500强与行业领先企业的商业领袖们，对于自己与家庭的联系，对于所在企业及行业发展及全球化与合作共赢均有了新的理解。

今年的“CDF之声”栏目，论坛秘书处邀请参会代表们以“我的2020”为题，分享过去一年来自己与他们所领导的企业、所在行业与国家的共同经历与感受。今天发声的是诺和诺德公司总裁兼首席执行官周赋德（Lars Fruergaard Jørgensen）。

在过去的27年间，诺和诺德扎根中国，建立了覆盖研发、生产和商业运营的全产业链布局。今天，中国已经成为诺和诺德的第二大市场。

2020年，新冠肺炎疫情对经济和社会造成了严重影响，但周赋德看到，为应对挑战，政府和社会加强了合作。

诺和诺德在中国的行动

周赋德认为，寻找可持续的方式来减少全球范围内存在的健康不平等问题是一项集体义务。

“我们赞赏中国有效地控制了国内疫情并向全球社会提供支持。中国领导人强烈呼吁建立‘人类卫生健康共同体’，诺和诺德愿意积极参与这一解决方案。”

在中国，诺和诺德持续助力“健康中国2030”行动，同时也将通过“循环零污染”环境战略和在产品、供应和业务运营中开展可循环利用的措施，响应中国对于早日实现碳中和的号召。

以下是视频中英文全文：

大家好！我是诺和诺德公司总裁兼首席执行官周赋德，非常荣幸受邀参加中国发展高层论坛2021年会。

诺和诺德是一家全球领先的生物制药公司，成立于1923年，总部位于丹麦。我们旨在推动改变，以战胜糖尿病和其他严重慢性疾病。为此，我们引领科研突破，扩大公司药物可及性，并致力于预防及最终治愈疾病。

诺和诺德与中国保持了特殊和长期的联系，我们致力于和政府及重要合作伙伴紧密合作，确保为中国1.29亿糖尿病患者提供更好的服务与支持。

因此，在过去的27年间，诺和诺德扎根中国，在当地建立了覆盖研发、生产和商业运营的全产业链布局。今天，中国已经成为我们的第二大市场。

全球新冠肺炎疫情对经济和社会造成了严重影响，但我们也看到涌现出各种不同和更加迅捷的方式来为我们面对的问题寻找解决方案。政府和社会加强合作应对挑战，人们更加基于解决方案来开展工作。

新冠肺炎疫情表明，寻找可持续的方式来减少全球范围内存在的健康不平等问题是一项集体义务。诺和诺德已经进一步承诺更好地支持脆弱的患者群体和高危人群 – 例如，确保救命药品的供给并在世界范围内向社会和社区提供支持。我们向50个中、低收入国家民众捐赠胰岛素的举动，受到了世界卫生组织总干事谭德赛博士的特别赞许。

同时，我们赞赏中国有效地控制了国内疫情并向全球社会提供支持。中国领导人强烈呼吁建立“人类卫生健康共同体”，诺和诺德愿意积极参与这一解决方案。

中国经济复苏的韧性以及兼顾国内发展和国际融合的“双循环”战略让我们印象深刻。在中国，诺和诺德助力当地创新，并受益于国内需求的增长在2020年实现了强劲增长。

在专注于满足医疗需求的同时，诺和诺德继续践行对中国的承诺，在2020年进博会期间宣布在上海新投资2亿元人民币，进一步拓展我们在中国的布局。

2021年是胰岛素发现100周年，但我们战胜糖尿病的征途远未止步。我们专注于通过预防、提升可及性和可负担性、创新来战胜糖尿病，并拓展到对肥胖症这一21世纪重大公共卫生挑战的关注和解决方案。在中国，我们通过合作持续助力“健康中国2030”行动，包括在六个主要城市开展“城市改变糖尿病”活动，以及为全国约130万人口提供糖尿病及并发症风险筛查服务。

最后，通过“循环零污染”环境战略，诺和诺德设立了在2030年之前实现碳中和的雄心，在产品、供应和业务运营中开展可循环利用。中国承诺在2030年之前实现碳达峰并在2060年之前实现碳中和，对此我们深受鼓舞。

中国发展高层论坛为政府、学术界、国际组织和商界领导人提供了重要的交流观点、相互启发的机会，来探讨如何利用多边合作解决全球挑战并促进可持续增长。

我非常感谢中国政府搭建这一重要的对话平台，预祝中国发展高层论坛2021年会取得圆满成功。

Hello， I am Lars Fruergaard Jørgensen， the President and CEO of Novo Nordisk． It is a great honour for me to be invited to the China Development Forum 2021．

Novo Nordisk is a leading global healthcare company， founded in 1923 and headquartered in Denmark． Our purpose is to drive change to defeat diabetes and other serious chronic diseases． We do so by pioneering scientific breakthroughs， expanding access to our medicines and working to prevent and ultimately cure disease．

Novo Nordisk has a special and long-standing tie with China， and we are committed to work in close partnership with the government， our valuable partners to make sure that we can better reach and support the 129 million people living with diabetes in China．

Therefore， deeply rooted in China for the past 27 years， Novo Nordisk has established a local presence covering the full value chain， from R&D， production to commercial operations． Today， China has become our second largest market．

The economic and social disruption caused by the global COVID-19 pandemic have been devastating from an economic and social perspective． But we are also seeing the emergence of different， more agile ways of developing new solutions to the problems we are facing． Public-private collaborations rise to the challenge， people work in an even more solutions-oriented way．

COVID-19 has demonstrated a collective obligation to find sustainable ways to reduce the health inequalities that exist on a global scale． In Novo Nordisk， we have strengthened our commitments to better support vulnerable patients and high-risk groups – for example by ensuring the supply of lifesaving medicines and supporting societies and communities worldwide． Our donation of insulin for people in 50 low- and middle-income countries was specifically acknowledged by WHO Director General Dr． Tedros．

At the same time， we commend China’s effective control of the pandemic domestically as well as support to the global community． The Chinese leadership has made a bold call for the need to establish “a global community of health for all” and Novo Nordisk is ready to be a very active part of the solution．

We are impressed by China’s resilience in economic recovery and advancing a “dual circulation” strategy combining domestic development and global integration． In China， Novo Nordisk contributes to local innovation and has achieved robust growth during 2020 as a consequence of increasing domestic demands．

While remaining focused on addressing unmet medical needs， Novo Nordisk has delivered on its commitment to China by announcing at CIIE 2020 a new investment in Shanghai of 200 million RMB to further expand our footprints in China．

2021 marks the 100th anniversary of the discovery of insulin， however our journey of defeating diabetes is far from over． We are dedicated to defeating diabetes with focus on prevention， access and affordability， innovation， as well as extending our focus and solutions to obesity， a major public health challenge for the 21st century． In China， we have made sustained contributions to the Healthy China 2030 initiatives through partnerships including “Cities Changing Diabetes” in six major cities and screening programs for around 1.3 million people across the country to detect the risk of diabetes and its complications．

Finally， with our “Circular for Zero” environmental strategy， we pursue an ambitious target of becoming carbon neutral by 2030 by taking on a circular approach to products， supply and business operations． To this end， we are encouraged by China’s pledge for carbon peak by 2030 and carbon neutrality by 2060．

The China Development Forum offers an important opportunity for governments， academia， international organisations and business leaders to exchange ideas and inspire each other on how we can mobilise multilateral partnerships to tackle global challenges and fuel sustainable growth． I appreciate China’s efforts in organizing such an important platform for dialogue and wish the CDF 2021 great success．

整理 - 昕奕

　　版权及免责声明：凡本网所属版权作品，转载时须获得授权并注明来源“融道中国”，违者本网将保留追究其相关法律责任的权力。凡转载文章，不代表本网观点和立场。

延伸阅读